1515
Annons
BioStock: Elicera Therapeutics comes out of the gate running in Q2

For Swedish immuno-oncology company Elicera Therapeutics, the highlight of Q2 was going public and being listed on Nasdaq First North Growth Market, all while raking in more than 60 MSEK in a share issue. The events came as the company had reached new heights with its development pipeline and technology platform, iTANK.

Read the article at biostock.se:

https://www.biostock.se/en/2021/08/elicera-therapeutics-comes-out-of-the-gate-running-in-q2/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se

Source: Cision
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1090kr
Prenumerera